GLPwatch
Papers (12034)
Page 84 of 201, ranked by citation count.
- Effects of Tirzepatide on Patients With Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Retrospective Cohort Study.
- Beta Cell Imaging-From Pre-Clinical Validation to First in Man Testing.
- Exendin‑4 inhibits lipotoxicity‑induced oxidative stress in β‑cells by inhibiting the activation of TLR4/NF‑κB signaling pathway.
- Effects of liraglutide vs. lifestyle changes on soluble suppression of tumorigenesis-2 (sST2) and galectin-3 in obese subjects with prediabetes or type 2 diabetes after comparable weight loss.
- SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs.
- Comparison of the effect of liraglutide and metformin therapy on the disease regulation and weight loss in obese patients with Type 2 diabetes mellitus.
- Tirzepatide adds hepatoprotection to its armoury.
- Effect of semaglutide on fatty liver disease biomarkers in patients with diabetes and obesity.
- Assessment of Changes in Body Composition After 3 Months of Dulaglutide Treatment.
- The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia.
- Exenatide mitigates inflammation and hypoxia along with improved angiogenesis in obese fat tissue.
- Insights into the central pathways involved in the emetic and behavioural responses to exendin-4 in the ferret.
- Pharmacotherapy for obesity.
- Exploring Connections Between Weight-Loss Medications and Thyroid Cancer: A Look at the FDA Adverse Event Reporting System Database.
- Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in type 2 diabetes.
- A pilot clinical study to Evaluate Liraglutide-mediated Anti-platelet activity in patients with type-2 Diabetes (ELAID study).
- GLP-1R activation restores Gas6-driven efferocytosis in senescent foamy macrophages to promote neural repair.
- Dulaglutide and insulin microsecretion in people with type 1 diabetes (DIAMOND-GLP-1): A randomized double-blind placebo-controlled trial.
- Effectiveness, persistence of use, and safety of orlistat and liraglutide in a group of patients with obesity.
- Real-world effectiveness of IDegLira compared with intensified conventional insulin therapy in adults with type 2 diabetes: a retrospective cohort study.
- Effects of Glucagon-like Peptide-1 Receptor Agonists and Sodium-glucose Cotransporter 2 Inhibitors on Cardiorenal and Metabolic Outcomes in People Without Diabetes.
- Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10).
- Exenatide-Modified Deferoxamine-Based Nanoparticles Ameliorates Neurological Deficits in Parkinson's Disease Mice.
- A randomized controlled trial investigating the effect of liraglutide on self-reported liking and neural responses to food stimuli in participants with obesity.
- Microneedle patch with pure drug tips for delivery of liraglutide: pharmacokinetics in rats and minipigs.
- Modified translationally controlled tumor protein-derived protein transduction domain enhances nasal delivery of exendin-4 as shown with insulin.
- Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial.
- Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysis.
- Liraglutide induced browning of visceral white adipose through regulation of miRNAs in high-fat-diet-induced obese mice.
- New association of bone morphogenetic protein 4 concentrations with fat distribution in obesity and Exenatide intervention on it.
- Mesenchymal stem cells combined with liraglutide relieve acute lung injury through apoptotic signaling restrained by PKA/β-catenin.
- Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals.
- Liraglutide for treating type 1 diabetes.
- Increased vision impairment reports linked to semaglutide: analysis of FDA adverse event data.
- The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Adolescents Without Diabetes Mellitus: A Systematic Review and Meta-Analysis.
- Improved metabolic efficacy of a dual amylin and calcitonin receptor agonist when combined with semaglutide or empagliflozin.
- Interactions between glucagon like peptide 1 (GLP-1) and estrogens regulates lipid metabolism.
- Growth Promotion and Increased ATP-Binding Cassette Transporters Expression by Liraglutide in Triple Negative Breast Cancer Cell Line MDA-MB-231.
- Glucagon-like peptide-1 receptor modulates cerebrospinal fluid secretion and intracranial pressure in rats.
- Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis.
- Off-label antiobesity treatment in patients without diabetes with GLP-1 agonists in clinical practice.
- Exendin-4 Improves Diabetic Kidney Disease in C57BL/6 Mice Independent of Brown Adipose Tissue Activation.
- Evaluating the Clinical Effectiveness and Safety of Semaglutide in Individuals with Uncontrolled Type 2 Diabetes. Real-World Evidence from Saudi Arabia: The Observational, Multicenter, 15-Month EVOLUTION Study.
- Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes.
- The fetal origins of the metabolic syndrome: can we intervene?
- Quantitative Impact of Plasma Clearance and Down-regulation on GLP-1 Receptor Molecular Imaging.
- Glucagon-like peptide-1 receptor activation stimulates PKA-mediated phosphorylation of Raptor and this contributes to the weight loss effect of liraglutide.
- Glucagon-like peptide-1 receptor expression after myocardial infarction: Imaging study using <sup>68</sup>Ga-NODAGA-exendin-4 positron emission tomography.
- Mortality Reduction in EMPA-REG OUTCOME Trial: Beyond the Antidiabetes Effect.
- Enhanced Oral Efficacy of Semaglutide via an Ionic Nanocomplex with Organometallic Phyllosilicate in Type 2 Diabetic Rats.
- Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes.
- Plasma proteomics reveals an improved cardio-metabolic profile in patients with type 2 diabetes post-liraglutide treatment.
- Elevated blood pressure, heart rate and body temperature in mice lacking the XLαs protein of the Gnas locus is due to increased sympathetic tone.
- Effects of semaglutide and empagliflozin on oxygenation, vascular autoregulation, and central thickness of the retina in people with type 2 diabetes: A prespecified secondary analysis of a randomised clinical trial.
- The effects of anti-obesity medications on bone metabolism: A critical appraisal.
- High-Dose Once-Weekly Semaglutide: A New Option for Obesity Management.
- Acute effects of the glucagon-like peptide-1 receptor agonist, exenatide, on blood pressure and heart rate responses to intraduodenal glucose infusion in type 2 diabetes.
- The effect of glucagon-like peptide-1 agonists on ocular parameters in idiopathic intracranial hypertension patients: a retrospective study.
- Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation.
- Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program.